Ownership history in RENAISSANCE TECHNOLOGIES LLC Β· 7 quarters on record
This page tracks every 13F SEC filing in which RENAISSANCE TECHNOLOGIES LLC reported a position in REVIVA PHARMACEUTCLS HLDGS I (RVPH). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price β sourced directly from SEC EDGAR 13F filings.
π RENAISSANCE TECHNOLOGIES LLC outperformed the S&P 500 by +41.9% annually on this RVPH position. Timing score: 17% (1/6 decisions correct). Average cost basis: $21.59. Maximum drawdown during holding period: β93.7%.
π₯ Exceptional β beat the S&P 500 by 41.9% per year on this position.
6 quarters analyzed
β οΈ Poor timing β buys often preceded drops, trims preceded rallies.
1 of 6 add/trim decisions correct
Best entry: $7.40 (2025 Q3) Β· Worst: $117.20 (2023 Q2)
πͺ Held through 2 major drawdowns (>20%).
6 adds Β· 1 trim. Bought during 3 of 4 down-price quarters. π Consistently bullish β fund kept accumulating this position.
βοΈ Portfolio weight has remained relatively stable β conviction maintained.
Currently 0.0% of portfolio
β Based on quarterly 13F SEC filings and end-of-quarter closing prices. Timing score = accuracy of add/trim decisions vs next-quarter price direction. Alpha = mean quarterly excess return Γ 4 (annualised). Not investment advice.
As of 2025 Q4 β sorted by position size